These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24556618)

  • 1. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.
    Murray J; Thomas H; Berry P; Kyle S; Patterson M; Jones C; Los G; Hostomsky Z; Plummer ER; Boddy AV; Curtin NJ
    Br J Cancer; 2014 Apr; 110(8):1977-84. PubMed ID: 24556618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
    Wang DD; Li C; Sun W; Zhang S; Shalinsky DR; Kern KA; Curtin NJ; Sam WJ; Kirkpatrick TR; Plummer R
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):89-98. PubMed ID: 27128213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
    Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
    Shapiro GI; Kristeleit RS; Burris HA; LoRusso P; Patel MR; Drew Y; Giordano H; Maloney L; Watkins S; Goble S; Jaw-Tsai S; Xiao JJ
    Clin Pharmacol Drug Dev; 2019 Jan; 8(1):107-118. PubMed ID: 29799676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
    Ihnen M; zu Eulenburg C; Kolarova T; Qi JW; Manivong K; Chalukya M; Dering J; Anderson L; Ginther C; Meuter A; Winterhoff B; Jones S; Velculescu VE; Venkatesan N; Rong HM; Dandekar S; Udar N; Jänicke F; Los G; Slamon DJ; Konecny GE
    Mol Cancer Ther; 2013 Jun; 12(6):1002-15. PubMed ID: 23729402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.
    Parrish KE; Cen L; Murray J; Calligaris D; Kizilbash S; Mittapalli RK; Carlson BL; Schroeder MA; Sludden J; Boddy AV; Agar NY; Curtin NJ; Elmquist WF; Sarkaria JN
    Mol Cancer Ther; 2015 Dec; 14(12):2735-43. PubMed ID: 26438157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.
    Znojek P; Willmore E; Curtin NJ
    Br J Cancer; 2014 Sep; 111(7):1319-26. PubMed ID: 25003660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How safe is rucaparib in ovarian cancer?
    Cosgrove CM; O'Malley DM
    Expert Opin Drug Saf; 2018 Dec; 17(12):1249-1255. PubMed ID: 30449210
    [No Abstract]   [Full Text] [Related]  

  • 10. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
    Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
    BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
    Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
    PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy.
    Destro G; Chen Z; Chan CY; Fraser C; Dias G; Mosley M; Guibbal F; Gouverneur V; Cornelissen B
    Nucl Med Biol; 2023; 116-117():108312. PubMed ID: 36621256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.
    McCrudden CM; O'Rourke MG; Cherry KE; Yuen HF; O'Rourke D; Babur M; Telfer BA; Thomas HD; Keane P; Nambirajan T; Hagan C; O'Sullivan JM; Shaw C; Williams KJ; Curtin NJ; Hirst DG; Robson T
    PLoS One; 2015; 10(2):e0118187. PubMed ID: 25689628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
    Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
    Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging PARP with [
    Chan CY; Chen Z; Destro G; Veal M; Lau D; O'Neill E; Dias G; Mosley M; Kersemans V; Guibbal F; Gouverneur V; Cornelissen B
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3668-3678. PubMed ID: 35614267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib.
    Kossatz S; Carney B; Farley C; Weber WA; Drain CM; Reiner T
    J Nucl Med; 2018 Aug; 59(8):1316-1320. PubMed ID: 29572258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
    Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
    J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
    Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
    Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.